• 1
    Clemons M, Goss P. Estrogen and the Risk of Breast Cancer. N Engl J Med. 2001; 344: 276285.
  • 2
    Key TJ, Chen J, Wang DY, Pike MC, Boreham J. Sex hormones in women in rural China and in Britain. Br J Cancer. 1990; 62: 631636.
  • 3
    Hankinson S, Willett W, Manson J, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1998; 90: 12921299.
  • 4
    Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998; 339: 16091618.
  • 5
    Borgna JL, Rochefort H. [Effects and mechanism of action of antiestrogens in breast cancer]. Sem Hop. 1984; 60: 703709.
  • 6
    Gail MH, Costantino JP, Bryant J, et al. Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer. J Natl Cancer Inst. 1999; 91: 18291846.
  • 7
    Salami S, Karami-Tehrani F. Biochemical studies of apoptosis induced by tamoxifen in estrogen receptor positive and negative breast cancer cell lines. Clin Biochem. 2003; 36: 247253.
  • 8
    Fornander T, Rutqvist LE. Adjuvant tamoxifen and second cancers. Lancet 1989; 1(8638): 616.
  • 9
    Grese TA, Dodge JA. Selective estrogen receptor modulators (SERMs). Curr Pharm Des. 1998; 4: 7192.
  • 10
    Haynes B, Dowsett M. Clinical pharmacology of selective estrogen receptor modulators. Drugs Aging. 1999; 14: 323336.
  • 11
    Jordan VC, Gottardis MM, Satyaswaroop PG. Tamoxifen-stimulated growth of human endometrial carcinoma. Ann N Y Acad Sci. 1991; 622: 439446.
  • 12
    Saga Y, Ohwada M, Kohno T, Takayashiki N, Suzuki M. High-grade endometrial stromal sarcoma after treatment with tamoxifen in a patient treated for breast cancer. Int J Gynecol Cancer. 2003; 13: 690692.
  • 13
    Lee YN, Lee HY, Chung HY, et al. In vitro induction of differentiation by ginsenosides in F9 teratocarcinoma cells. Eur J Cancer. 1996; 32: 14201428.
  • 14
    Lee YN, Lee HY, Lee YM, et al. Involvement of glucocorticoid receptor in the induction of differentiation by ginsenosides in F9 teratocarcinoma cells. J Steroid Biochem Mol Biol. 1998; 67: 105111.
  • 15
    Lee Y, Jin Y, Lim W, et al. A ginsenoside-Rh1, a component of ginseng saponin, activates estrogen receptor in human breast carcinoma MCF-7 cells. J Steroid Biochem Mol Biol. 2003; 84: 463468.
  • 16
    Gray SL, Lackey BR, Tate PL, Riley MB, Camper ND. Mycotoxins in root extracts of American and Asian ginseng bind estrogen receptors alpha and beta. Exp Biol Med (Maywood). 2004; 229: 560568.
  • 17
    Chan RY, Chen WF, Dong A, Guo D, Wong MS. Estrogen-like activity of ginsenoside Rg1 derived from Panax notoginseng. J Clin Endocrinol Metab. 2002; 87: 36913695.
  • 18
    Duda RB, Kang SS, Archer SY, Meng S, Hodin RA. American ginseng transcriptionally activates p21 mRNA in breast cancer cell lines. J Korean Med Sci. 2001; 16( suppl): S54S60.
  • 19
    Oh M, Choi YH, Choi S, et al. Anti-proliferating effects of ginsenoside Rh2 on MCF-7 human breast cancer cells. Int J Oncol. 1999; 14: 869875.
  • 20
    Chen D, Zhao Y, Bai S, Shi Z, Zhang J. [Effect of ginsenoside Rg3 on the progression of orthotopically xenotransplanted human breast cancer in nude mice and its mechanism]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2003; 34: 546548.
  • 21
    Bae EA, Han MJ, Choo MK, Park SY, Kim DH. Metabolism of 20(S)- and 20(R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities. Biol Pharm Bull. 2002; 25: 5863.
  • 22
    Tawab MA, Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration. Drug Metab Dispos. 2003; 31(8): 10651071.
  • 23
    Jia W, Yan H, Bu X, Liu G, Zhao Y. Aglycone protopanaxadiol, a ginseng saponin inhibits P-glycoprotein and sensitizes chemotherapy drugs on multidrug resistant cancer cells [abstract]. J Clin Oncol. 2004 ASCO Meeting Proceedings (Post-Meeting Edition). 2004; 22:(Jul 15 suppl). Abstract 9663.
  • 24
    Faridi J, Wang L, Endemann G, Roth RA. Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin Cancer Res. 2003; 9: 29332939.
  • 25
    Jordan NJ, Gee JM, Barrow D, Wakeling AE, Nicholson RI. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res Treat. 2004; 87: 167180.
  • 26
    Snyder KR, Sparano N, Malinowski JM. Raloxifene hydrochloride. Am J Health Syst Pharm. 2000; 57: 16691675; quiz 76–78.
  • 27
    Szucs J, Pavo I, Jurida N. [Clinical experience with raloxifene]. Orv Hetil. 2000; 141: 237240.
  • 28
    Hubbard RE, Pike ACW, Brzozowski AM, et al. Structural insights into the mechanisms of agonism and antagonism in oestrogen receptor isoforms. Eur J Cancer. 2000; 36( suppl 4): 1718.
  • 29
    Goldstein SR. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women's health. Int J Fertil Womens Med. 1999; 44: 221226.
  • 30
    Kristensen B, Ejlertsen B, Dalgaard P, et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol. 1994; 12: 992997.
  • 31
    Kanter-Lewensohn L, Girnita L, Girnita A, et al. Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway. Mol Cell Endocrinol. 2000; 165: 131137.
  • 32
    Koh J, Kubota T, Koyama T, et al. Combined antitumor activity of 7-hydroxystaurosporine (UCN-01) and tamoxifen against human breast carcinoma in vitro and in vivo. Breast Cancer. 2003; 10: 260267.
  • 33
    Ramachandran C, Khatib Z, Petkarou A, et al. Tamoxifen modulation of etoposide cytotoxicity involves inhibition of protein kinase C activity and insulin-like growth factor II expression in brain tumor cells. J Neurooncol. 2004; 67: 1928.
  • 34
    Frogne T, Jepsen JS, Larsen SS, Fog CK, Brockdorff BL, Lykkesfeldt AE. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr Relat Cancer. 2005; 12: 599614.
  • 35
    deGraffenried LA, Friedrichs WE, Russell DH, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res. 2004; 10(23): 80598067.
  • 36
    Akao T, Kida H, Kanaoka M, Hattori M, Kobashi K. Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. J Pharm Pharmacol. 1998; 50: 11551160.
  • 37
    Bae EA, Park SY, Kim DH. Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull. 2000; 23: 14811485.
  • 38
    Hasegawa H, Suzuki R, Nagaoka T, Tezuka Y, Kadota S, Saiki I. Prevention of growth and metastasis of murine melanoma through enhanced natural-killer cytotoxicity by fatty acid-conjugate of protopanaxatriol. Biol Pharm Bull. 2002; 25: 861866.